收费全文 | 54661篇 |
免费 | 7271篇 |
国内免费 | 1455篇 |
耳鼻咽喉 | 221篇 |
儿科学 | 1120篇 |
妇产科学 | 745篇 |
基础医学 | 2940篇 |
口腔科学 | 2460篇 |
临床医学 | 8225篇 |
内科学 | 6070篇 |
皮肤病学 | 902篇 |
神经病学 | 2796篇 |
特种医学 | 908篇 |
外国民族医学 | 10篇 |
外科学 | 5374篇 |
综合类 | 9992篇 |
现状与发展 | 6篇 |
一般理论 | 26篇 |
预防医学 | 5038篇 |
眼科学 | 825篇 |
药学 | 6968篇 |
477篇 | |
中国医学 | 5277篇 |
肿瘤学 | 3007篇 |
2024年 | 251篇 |
2023年 | 1220篇 |
2022年 | 1996篇 |
2021年 | 3263篇 |
2020年 | 3636篇 |
2019年 | 2787篇 |
2018年 | 2583篇 |
2017年 | 2803篇 |
2016年 | 2711篇 |
2015年 | 2323篇 |
2014年 | 4029篇 |
2013年 | 4442篇 |
2012年 | 3536篇 |
2011年 | 3658篇 |
2010年 | 2876篇 |
2009年 | 2501篇 |
2008年 | 2435篇 |
2007年 | 2457篇 |
2006年 | 2147篇 |
2005年 | 1754篇 |
2004年 | 1498篇 |
2003年 | 1345篇 |
2002年 | 1072篇 |
2001年 | 842篇 |
2000年 | 681篇 |
1999年 | 516篇 |
1998年 | 439篇 |
1997年 | 402篇 |
1996年 | 339篇 |
1995年 | 282篇 |
1994年 | 284篇 |
1993年 | 180篇 |
1992年 | 212篇 |
1991年 | 175篇 |
1990年 | 153篇 |
1989年 | 151篇 |
1988年 | 142篇 |
1987年 | 125篇 |
1986年 | 85篇 |
1985年 | 168篇 |
1984年 | 156篇 |
1983年 | 96篇 |
1982年 | 97篇 |
1981年 | 85篇 |
1980年 | 81篇 |
1979年 | 74篇 |
1978年 | 56篇 |
1977年 | 47篇 |
1976年 | 48篇 |
1975年 | 58篇 |
Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献
Areas covered: We report on medication use research and have conducted a systematic review of observational studies on medication use to provide an updated overview on characteristics, objectives, methods, and patterns in hospitalized neonates. Moreover, a review on aspects of medication use for opioids, anti-epileptics, gastric acid-related disorders and respiratory stimulants with emphasis on trends and impact of interventions is presented, illustrating how research on medication use can contribute to improved neonatal pharmacotherapy and more focused research. Medication use reports describe patterns and provide signals on irrational use, benchmarking, or can guide research priorities. Moreover, this may generate information on how neonatal health topics and their pharmacotherapy are handled over time or across regions.
Expert opinion: Research on medicine utilization is relevant, since it will inform us on aspects like trends, variability, or about the impact and pattern of implementation of guidelines in neonates. Further progress necessitates to merge datasets on medication use with clinical characteristics, and perinatal drug use remains an area in need of additional research. 相似文献